Business, energy, technology, markets and global industry news from Business News Today

Summit Therapeutics Inc.

PharmaDeviceNews Summit Therapeutics Inc.
Pharma & Biotech

Summit Therapeutics has $2bn from AstraZeneca and stronger cancer survival data, but will the FDA approve ivonescimab?

Summit Therapeutics has secured a $2 billion strategic equity investment from AstraZeneca while expanding the global development programme for ivonescimab. However, the November 14 FDA decision remains uncertain because the original HARMONi overall-survival analysis did not achieve statistical significance, despite favourable results from subsequent analyses and separate Chinese trials.

Read More
Editorial infographic illustrating Summit Therapeutics’ global Phase 2 kidney cancer trial, featuring anatomical kidney imagery, a clinical trial document, a world map, and highlights of ivonescimab combination therapies compared with established immunotherapy.
Pharma & Biotech

Summit Therapeutics expands ivonescimab development with SMT112-216 trial

Summit Therapeutics opens a global Phase 2 kidney cancer trial testing ivonescimab combinations against established immunotherapy. What comes next?

Read More
Summit Therapeutics’ updated HARMONi analysis strengthens the ivonescimab survival trend in Western and Asian lung cancer patients ahead of the FDA decision. Representative image.
Pharma & Biotech

Summit Therapeutics nears FDA decision with stronger ivonescimab survival signal

Ivonescimab’s updated HARMONi survival trend strengthens before the FDA’s November decision, but key statistical details remain undisclosed.

Read More
Representative image: A clinician reviews lung cancer imaging as ivonescimab survival data from the HARMONi-6 study raise fresh questions about the future of first-line squamous non-small cell lung cancer treatment.
Pharma & Biotech

Can Summit and Akeso turn ivonescimab into a global lung cancer challenger?

Ivonescimab showed an overall survival benefit in HARMONi-6. Read how the data could reshape first-line squamous NSCLC treatment.

Read More